| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.87 [0.66, 1.14] | | < 1 | | 0% | 1 study (1/-) | 84.1 % | NA | not evaluable | | crucial | - |
| MFS | 0.73 [0.56, 0.96] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | important | - |
| RFS (extension) | 0.71 [0.59, 0.85] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| RFS/DFS | 0.61 [0.49, 0.75] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | low | not evaluable | high | important | - |
safety endpoints 00 |
| AE (any grade) | 0.49 [0.20, 1.23] | | < 1 | | 0% | 1 study (1/-) | 93.6 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 0.28 [0.21, 0.37] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.74 [0.07, 44.47] | | < 1 | | 97% | 3 studies (3/-) | 37.0 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 1.73 [0.05, 61.70] | | < 1 | | 97% | 3 studies (3/-) | 38.4 % | low | not evaluable | high | non important | - |
| SAE (any grade) | 2.18 [0.76, 6.21] | | < 1 | | 71% | 2 studies (2/-) | 7.3 % | low | not evaluable | high | non important | - |
| SAE (grade 3-4) | 3.06 [1.65, 5.67] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| STRAE (any grade) | 5.79 [2.74, 12.21] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| STRAE (grade 3-4) | 5.30 [2.27, 12.38] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| TRAE (any grade) | 1.66 [0.18, 15.50] | | < 1 | | 94% | 3 studies (3/-) | 33.0 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 1.91 [0.12, 29.55] | | < 1 | | 97% | 3 studies (3/-) | 32.4 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 0.53 [0.07, 4.21] | | < 1 | | 0% | 3 studies (3/-) | 72.5 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 2.01 [0.06, 73.17] | | < 1 | | 98% | 3 studies (3/-) | 35.4 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.93 [0.04, 97.28] | | < 1 | | 97% | 3 studies (3/-) | 37.4 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.74 [0.09, 6.38] | | < 1 | | 0% | 3 studies (3/-) | 60.7 % | low | not evaluable | high | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 1.45 [0.11, 19.13] | | < 1 | | 0% | 2 studies (2/-) | 39.0 % | low | not evaluable | high | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 0.69 [0.17, 2.85] | | < 1 | | 0% | 3 studies (3/-) | 69.6 % | low | not evaluable | high | non important | - |
| Alopecia TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Anaemia TRAE (grade 3-4) | 1.45 [0.11, 19.13] | | < 1 | | 0% | 2 studies (2/-) | 39.0 % | low | not evaluable | high | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.71 [0.14, 3.63] | | < 1 | | 0% | 3 studies (3/-) | 65.8 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 0.25 [0.03, 2.24] | | < 1 | | 0% | 1 study (1/-) | 89.1 % | NA | not evaluable | | non important | - |
| Blood and lymphatic system disorders TRAE (grade 3-4) | 3.02 [0.28, 33.13] | | < 1 | | 0% | 2 studies (2/-) | 18.5 % | low | not evaluable | high | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.91 [0.02, 46.72] | | < 1 | | 0% | 1 study (1/-) | 51.8 % | NA | not evaluable | | non important | - |
| Chills TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Colitis TRAE (grade 3-4) | 3.11 [0.28, 34.14] | | < 1 | | 0% | 2 studies (2/-) | 17.8 % | low | not evaluable | high | non important | - |
| Cough TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Diabetes TRAE (grade 3-4) | 1.23 [0.17, 8.82] | | < 1 | | 0% | 3 studies (3/-) | 41.8 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.35 [0.07, 1.76] | | < 1 | | 41% | 3 studies (3/-) | 89.7 % | low | not evaluable | high | non important | - |
| Dizziness TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Dyspepsia TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 4.00 [0.64, 25.16] | | < 1 | | 0% | 2 studies (2/-) | 7.0 % | low | not evaluable | high | non important | - |
| Eye disorders TRAE (grade 3-4) | 1.45 [0.11, 19.13] | | < 1 | | 0% | 2 studies (2/-) | 39.0 % | low | not evaluable | high | non important | - |
| Fatigue TRAE (grade 3-4) | 0.60 [0.14, 2.55] | | < 1 | | 0% | 3 studies (3/-) | 75.7 % | low | not evaluable | high | non important | - |
| Gastritis TRAE (grade 3-4) | 2.32 [0.20, 26.84] | | < 1 | | 0% | 2 studies (2/-) | 25.1 % | low | not evaluable | high | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 1.04 [0.04, 29.48] | | < 1 | | 89% | 3 studies (3/-) | 49.0 % | low | not evaluable | high | non important | - |
| General disorders and administration site conditions TRAE (grade 3-4) | 2.32 [0.20, 26.84] | | < 1 | | 0% | 2 studies (2/-) | 25.1 % | low | not evaluable | high | non important | - |
| Headache TRAE (grade 3-4) | 0.28 [0.05, 1.51] | | < 1 | | 0% | 3 studies (3/-) | 92.9 % | low | not evaluable | high | non important | - |
| Hepatitis TRAE (grade 3-4) | 3.40 [0.79, 14.57] | | < 1 | | 0% | 2 studies (2/-) | 5.0 % | low | not evaluable | high | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 1.42 [0.07, 29.90] | | < 1 | | 91% | 3 studies (3/-) | 41.2 % | low | not evaluable | high | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 2.01 [0.07, 59.97] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Hypertension TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.92 [0.31, 11.76] | | < 1 | | 0% | 3 studies (3/-) | 24.2 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.29 [0.08, 1.03] | | < 1 | | 0% | 3 studies (3/-) | 97.2 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.66 [0.11, 4.08] | | < 1 | | 0% | 3 studies (3/-) | 67.1 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 1.04 [0.07, 14.37] | | < 1 | | 84% | 3 studies (3/-) | 48.9 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.55 [0.11, 22.65] | | < 1 | | 89% | 3 studies (3/-) | 37.6 % | low | not evaluable | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.80 [0.56, 5.76] | | < 1 | | 16% | 2 studies (2/-) | 16.2 % | low | not evaluable | high | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.37 [0.04, 3.82] | | < 1 | | 31% | 3 studies (3/-) | 79.6 % | low | not evaluable | high | non important | - |
| Metabolism and nutrition disorders TRAE (grade 3-4) | 1.29 [0.15, 11.24] | | < 1 | | 0% | 2 studies (2/-) | 40.9 % | low | not evaluable | high | non important | - |
| Musculoskeletal and connective tissue disorders TRAE (grade 3-4) | 0.96 [0.03, 31.61] | | < 1 | | 63% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 0.96 [0.09, 10.77] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | low | not evaluable | high | non important | - |
| Myositis TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Nausea TRAE (grade 3-4) | 1.29 [0.15, 11.14] | | < 1 | | 0% | 3 studies (3/-) | 40.8 % | low | not evaluable | high | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 1.07 [0.16, 7.27] | | < 1 | | 0% | 2 studies (2/-) | 47.3 % | low | not evaluable | high | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 1.45 [0.11, 19.13] | | < 1 | | 0% | 2 studies (2/-) | 39.0 % | low | not evaluable | high | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 0.32 [0.04, 2.43] | | < 1 | | 0% | 3 studies (3/-) | 86.2 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.99 [0.14, 6.74] | | < 1 | | 0% | 3 studies (3/-) | 50.5 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 0.35 [0.13, 0.98] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 1.00 [0.02, 50.62] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 0.37 [0.05, 2.77] | | < 1 | | 0% | 3 studies (3/-) | 83.4 % | low | not evaluable | high | non important | - |
| Sarcoidosis TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 0.75 [0.09, 6.51] | | < 1 | | 68% | 3 studies (3/-) | 60.2 % | low | not evaluable | high | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 1.45 [0.11, 19.13] | | < 1 | | 0% | 2 studies (2/-) | 39.0 % | low | not evaluable | high | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Uveitis TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Vomiting TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.96 [0.06, 15.59] | | < 1 | | 0% | 2 studies (2/-) | 51.1 % | low | not evaluable | high | non important | - |
